Tianwu Tech Secures Tens of Millions in Pre-A Funding to Advance AI-Powered Protein Design Platform AccelProtein™
Matwings Technology
AI Protein Design Service Provider
Recently, Matwings Technology, a high-tech enterprise focused on providing AI protein design services, announced the successful completion of a multi-million yuan Pre-A round of financing. This round of financing was led by金沙江联合资本 (Jinsha River United Capital), with participation from本草资本 (BioHeritage Capital), 晓池资本 (Xiaochi Capital), and 四川交研资本 (Sichuan Jiaoyan Capital).The funds raised will be mainly used to accelerate the industry application of a general large model for protein engineering, promoting industrial upgrading.
Matwings Technology was founded in 2021 by an elite team from Shanghai Jiao Tong University. It is one of the earliest companies in China to develop AI protein large models and is currently the largest AI protein design service provider in China.
AccelProtein™ Large Model
Across Protein 3D Structure
From Sequence to Function: Precision Protein Design
Matwings Technology's independently developedAI Protein Design Large Model —— AccelProtein™, it adopts the advanced Transformer architecture and masked language model. Trained on complex data comprising 780 million protein sequences of organisms across various environments, the model has mastered the intricate semantic relationships between protein sequences and their functions, enabling end-to-end prediction from "sequence to function."With genuine zero-shot prediction capability.
Use"AccelProtein™ Large Model Automatic Design + Minimal Experimental Validation" Can Design All Types of Protein Sequences, and multiple proteins designed with its participation inStability, Activity, Affinity, etc.Important indicators,Reached and even surpassed the world's leading level, the time required for protein design has also decreased fromTraditionally 2-5 years significantly shortened to 2-6 months. This is not only a major technological leap, but also a profound impact on the entire field of biological science, marking that protein engineering, driven by AI technology, is moving fromFrom the Traditional Bioengineering Era to the Intelligent Bioengineering Era, bringing more precise bio-system design to humanity.
With the self-developed AI protein design large model AccelProtein™,Matwings Technology has solvedTraditional "Expert Experience & Extensive Trial-and-Error" ParadigmProtein design takes a long time, is costly, has a low positive rate, and is difficult to optimize across multiple metrics.And other core issues, inIn terms of enhancing customer product performance, shortening R&D cycles, reducing production costs, and establishing a high-barrier patent layoutHas played a significant role.
In just over two years, Matwings Technology has successfullyDelivered more than ten protein design projects, gaining recognition from several leading clients in the industry and establishing close, long-term strategic partnerships with numerous upstream and downstream enterprises. Currently, the company's technical services have expanded into multiple fields, includingInnovative drugs, in vitro diagnostics, nutritional health, food and beverages, beauty and skincare, cleaning and textiles, bioenergy, bioagriculture, and environmental engineering, etc.`, showcasing its extensive influence and technical strength in the field of protein design.`
“
Professor Liang Hong, founder and chief scientist of Matwings Technology, stated:
At a time when the biopharmaceutical investment sector is generally experiencing a downturn, Matwings Technology has gained the favor of investors, fully demonstrating the confidence of top-tier investment institutions in the company’s business model and the future development prospects of its AI protein design large model, AccelProtein™. After the completion of this new round of financing, we will continue to innovate and refine our technology, accelerate the industrial application of the general large model for protein engineering, contribute to industrial upgrading, and promote the prosperity and development of human society.
“
Ms. Wang Xiaoyan, Managing Partner of Jinsha River United Capital Biomedical Fund, stated:
As the lead investor of Matwings Technology, we have great confidence in this team. They are not only technologically advanced but also demonstrate outstanding market performance. In particular, their self-developed large AI model for protein design represents a revolutionary breakthrough for industries such as biomedicine. We are optimistic about Matwings Technology's strong scientific research capabilities and clear commercial roadmap, and believe that they will continue to deepen their expertise in the field of AI protein design, drive industry innovation, and create more value for partners and customers.
“
Dr. Liu Qianye, partner of 3E Bioventures Capital, stated:
In an era where large language models are flourishing and AI-empowered pharmaceutical research and development companies are emerging one after another, Matwings Technology has trained a large model using the language of proteins in nature — amino acid sequences. This allows for the rapid retrieval of high-quality multi-point mutants in high-dimensional phase space, greatly improving the efficiency of protein engineering. Matwings Technology has collaborated with multiple pharmaceutical and biotech companies, achieving breakthrough progress. We look forward to this AI-powered protein design technology empowering more biotech companies.
“
Mr. Xu Junhao, Investment Director of Xiaochi Capital, stated:
Matwings Technology, with its strong technical capabilities, combines AI and synthetic biology—two popular and cutting-edge technologies—and has gained recognition from several leading clients in the industry. Relying on its advanced large-scale AI protein design model and extensive experimental operation experience, it greatly enhances the R&D and technological iteration efficiency of partner companies through a combination of "dry and wet lab" experiments. Xiaochi Capital also looks forward to Matwings Technology injecting more innovative productivity into the biopharmaceutical and biomanufacturing industries.
“
Mr. Yang Guang, founding partner of Yaotu Capital, stated:
Matwings Technology Team Possesses Strong Algorithm, Technical, and Iteration Capabilities, Independently Developing a General Large Model Based on High-Quality Protein Data, Achieving Technological Breakthroughs in the Field of Protein Design, and Has Already Gained Recognition from Dozens of Well-Known Enterprises in the Industry. Glory Capital Highly Values the Company's Development and Looks Forward to Matwings Technology Becoming a Global Leader in the AI Protein Design Field.
“
Mr. Fang Zhenghao, Managing Partner of Xiaomiao Langcheng, stated:
As an angel investor of Matwings Technology, I am deeply honored to witness its rapid growth into a leading player in the field of AI-driven protein design services in China. Since its establishment, Matwings Technology has achieved remarkable success in protein design through its innovative large-scale AI model technology, bringing revolutionary changes to multiple industries such as pharmaceuticals, bioengineering, and manufacturing. We sincerely congratulate Matwings Technology on securing a new round of financing amid the capital winter, believing this will inject even stronger momentum into the company’s development. May Matwings Technology continue to focus on technological innovation, constantly push boundaries, and make greater contributions to advancing the biomanufacturing industry and promoting human health. Matwings soars high—its future is promising!
E.N.D
Previous article recommendations:
NeuroD1 Gene Therapy by Shenxi Biotechnology Successfully Administers First Patient Globally
JW Therapeutics' CAR-T Product "Relma-cel" Achieves RMB 174 Million in Sales in 2023
Fosun Pharma Subsidiary's NK Cell Therapy GCK-01 Approved for Clinical Trials
First in China, Yaotang Biotech's In Vivo Gene Editing Drug YOLT-201 Approved for Clinical Trials
The First AAV Gene Therapy for Hemophilia A Fell Far Short of Sales Expectations Last Year